BTTC Investigators Publish Paper in Neuro-Oncology Journal
The primary objective of this factorial phase II study was to determine if one of 3 potential chemotherapy agents added to dose-dense temozolomide (ddTMZ) improves progression-free survival for patients with newly diagnosed glioblastoma. A prior phase I trial established the safety of combining ddTMZ with isotretinoin, celecoxib, and/or thalidomide. The results do not establish a benefit for these combinations but indicate that adding isotretinoin to ddTMZ may be detrimental. This study did, however, demonstrate how the factorial design is efficient in testing drug combinations in newly diagnosed glioblastoma.
To read the Neuro-Oncology Journal Article, click here.